OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Inside the Clinic: JTCC Experts Share Strategies for When CAR T-Cell Therapy Is Not an Option

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, share strategies for when CAR T-cell therapy is not an option.

Inside the Clinic: JTCC Experts Discuss Approaches to CAR T-Cell Therapy

March 15th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss approaches to CAR T-cell therapy.

Dr. Bardia on the Rationale of Utilizing Endocrine Therapy in ER+ Breast Cancer

March 14th 2022

Aditya Bardia, MD, MPH, discusses the use of endocrine therapy in estrogen receptor–positive breast cancer.

Dr. Petrylak on the Rationale of the EV-103 Trial in MIBC

March 14th 2022

Daniel P. Petrylak, MD, discusses the rationale for of the phase 1b/2 EV-103 trial in patients with muscle-invasive bladder cancer.

Dr. Badani on the Evolution of Robotic Retroperitoneal Partial Nephrectomies in RCC

March 14th 2022

Ketan K. Badani, MD, discusses the evolution of robotic retroperitoneal partial nephrectomies in renal cell carcinoma.

Dr. Davidson on the Future of HER2-Targeted Therapies in Breast Cancer

March 14th 2022

Nancy E. Davidson, MD, discusses the future of HER2-targeted therapies in breast cancer.

Dr. Birrer on Remaining Questions in Platinum-Sensitive Ovarian Cancer

March 12th 2022

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

Dr. Olawaiye on the Social and Biological Determinants of Disparities in Women’s Cancer

March 12th 2022

Alexander B. Olawaiye, MD, discusses the social and biological determinants of disparities in women’s cancer.

Dr. Park on the Dosing Strategies Utilized in the FELIX Trial in R/R ALL

March 10th 2022

Jae Park, MD, discusses dosing strategies utilized in the phase 1/2 FELIX trial in relapsed/refractory acute lymphoblastic leukemia.

Dr. Roddie on the Potential Utilization of Obe-Cel in R/R ALL

March 10th 2022

Claire Roddie, MD, discusses the potential utilization of obecabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.

Dr. Uy on the Efficacy Findings from a Phase 1/2 Trial in R/R AML

March 10th 2022

Geoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.

Inside the Clinic: JTCC Experts Highlight Optimal Strategies for CAR T-Cell–Related AEs

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss optimal strategies for CAR T-cell–related adverse effects.

Inside the Clinic: JTCC Experts Discuss Retreatment With CAR T-Cell Therapy

March 10th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss retreatment with CAR T-cell therapy.

Dr. Hurvitz on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer with Brain Metastases

March 9th 2022

Sara A. Hurvitz, MD, discusses the benefit of trastuzumab deruxtecan in a subset of patients with HER2-positive breast cancer and active brain metastases in the phase 3 DESTINY-Breast03 trial.

Dr. Tolaney on Pivotal Trials in HER2+ Breast Cancer

March 9th 2022

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

Inside the Clinic: JTCC Experts Highlight Next Steps With CAR T-Cell Therapy

March 9th 2022

Lori A. Leslie, MD, and Andre H. Goy, MD, discuss next steps with CAR T-cell therapy.

Dr. Ramnaraign on Sequencing IO and TKI Combinations in Metastatic RCC

March 8th 2022

Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.

Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL

March 8th 2022

Lori A. Leslie, MD, discusses the methods utilized in the phase 3 ZUMA‑7 trial in relapsed/refractory large B-cell lymphoma.

Dr. Hurvitz on the Clinical Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 8th 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

Dr. Larocca on What to Know when Diagnosing Difficult-to-Treat Patients in Multiple Myeloma

March 8th 2022

Alessandra Larocca, MD, PhD, discusses what to know when diagnosing difficult-to-treat patients with multiple myeloma.